Safety and Efficacy of an Infant Starter Formula With Prebiotics (GOS) and a Higher Content of Beta-palmitate on Stool Characteristics, Food Tolerance, Calcium Uptake, and Incidence of Infectious Disease in the First Year of Life
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Infections
- Sponsor
- Waldkrankenhaus Protestant Hospital, Spandau
- Enrollment
- 128
- Locations
- 1
- Primary Endpoint
- number of gastrointestinal infections
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The purpose of this clinical trial is to evaluate the effect of a new infant starter formula with added prebiotics (GOS) and with a fat blend rich in beta-palmitate.
Detailed Description
An experimental infant formula with added prebiotics (GOS) and with a higher content of palmitic acid esterified in beta-position is to be tested in a double-blinded randomized controlled trial. The addition of prebiotics to an infant formula should favor growth of a beneficial bifidogenic intestinal flora and have positive effects on immunity, promote softer stool formation and short chain fatty acid content in the stools. Higher proportion of beta-palmitic acid esterified in 2nd position of the triglyceride should reduce formation of fatty acid-calcium soaps in the stools and promote calcium and fat absorption in the gut, therfor reduce symptoms of constipation and colics.
Investigators
Antonia Nomayo, MD
MD
Waldkrankenhaus Protestant Hospital, Spandau
Eligibility Criteria
Inclusion Criteria
- •healthy term neonates
- •gestational age 37 to 42 weeks
- •birth weight 10th to 90th percentile (Voigt reference)
- •infants being exclusively formula-fed at enrollment
Exclusion Criteria
- •infants with high risk of atopic disease due to family history
- •congenital disorder or syndrome with need for special diet / impairment of growth
- •antibiotic medication prior to enrollment
Outcomes
Primary Outcomes
number of gastrointestinal infections
Time Frame: within first year of life
Secondary Outcomes
- number of infectious episodes (gastrointestinal, respiratory, fever episodes)(within first year of life)
- symptoms of food intolerance, constipation, colics(after 6 weeks, 12 weeks intervention)
- atopic manifestation(within 1st year of life)
- anthropometric parameters (gain in weight, length, head circumference)(after 6 weeks, after 12 weeks intervention)
- proportion of bifidobacteria on total stool bacteria(after 6 and 12 weeks intervention)
- stool biochemistry (calcium-fatty acid soaps, short chain fatty acids content in the stools)(after 6 weeks, 12 weeks intervention)
- calcium absorption(after 6 weeks, 12 weeks intervention)
- erythrocytes´ fatty acid profile(after 6 weeks intervention)